Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

942442

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Spondyloarthritis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the guidance issued by NICE on Spondyloarthritis QS170, in June 2018 is implemented effectively throughout the UK; and if he will make a statement.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	164432
answer	answer is ministerial correction date of answer 19/07/2018 answer text <p>On 28 June 2018, the National Institute for Health and Care Excellence (NICE) published a new Quality Standard (QS) on spondyloarthritis. QSs are important in setting out to patients, the public, commissioners and providers what a high-quality service should look like in a particular area of care. Whilst providers and commissioners must have regard to NICE QSs in planning and delivering services, they do not provide a comprehensive service specification and implementation of QSs is not mandatory.</p><p> </p><p>The way NICE was established in legislation means that its guidance is officially for England only. However, NICE has agreements to provide certain NICE products and services to Wales, Scotland and Northern Ireland. Decisions on how NICE guidance is applied in these countries are made by the devolved administrations.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/07/2018 15:15:00 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

942445

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Brain: Tumours
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish how the Government allocates new funding for (a) the Tessa Jowell Brain Cancer Research Mission and (b) other brain tumour research.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	164435
answer	answer is ministerial correction date of answer 24/07/2018 answer text <p>The Department’s funding for all brain tumour research will be invested through the National Institute for Health Research (NIHR). The NIHR focusses on supporting health and care research, and translating discoveries into practical products, treatments, devices and procedures.</p><p> </p><p>Applications to the NIHR for research funding are subject to scientific peer review, with awards being made on the basis of value for money, scientific quality and the importance of the topic to patients and health and care services. Details on the NIHR’s general assessment criteria can be found at the following link:</p><p> </p><p><a href="https://www.nihr.ac.uk/funding-and-support/documents/funding-for-research-studies/how-to-apply/general-assessment-criteria.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/funding-for-research-studies/how-to-apply/general-assessment-criteria.pdf</a></p><p> </p><p>We are relying on researchers to submit high-quality research proposals in this very difficult area. To encourage such applications we have released an NIHR Highlight Notice on brain tumour research asking research teams to submit collaborative applications building on recent initiatives and investments. We are also working closely with research funding partners such as Cancer Research UK, the Medical Research Council, and brain tumour charities, who fund research into new scientific discoveries. We stand ready to translate these new discoveries as quickly as possible into new treatments and diagnostics for patients via the NIHR.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 24/07/2018 10:42:27 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

942479

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cervical Cancer: Lincolnshire
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of trends in the average time that patients waited to receive cervical screening results in Lincolnshire in each of the last three years.
tabling member constituency	Lincoln
tabling member printed	Karen Lee
uin	164526
answer	answer is ministerial correction date of answer 24/07/2018 answer text <p>No assessment has been made of trends in the average time that patients waited to receive cervical screening results.</p><p> </p><p>The NHS Cervical Screening Programme has a quality measure referred to as cervical screening turnaround time. This is a quality measure which recommends that the optimal turnaround time for which a woman should receive her screening result in writing is 14 days from the date the sample is taken. This data is provided monthly and is shared with the cervical screening programme boards and NHS England commissioners that oversee services so that performance and trends can be monitored locally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/07/2018 10:46:06 answering member 4067 label Biography information for Steve Brine
tabling member	4664 label Biography information for Karen Lee

942504

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Fracking: Health Hazards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the Government has commissioned a review of research relating to the health implications of shale gas extraction by any organisation since the 2015 general election.
tabling member constituency	Totnes
tabling member printed	Dr Sarah Wollaston
uin	164421
answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>Public Health England continues to review the evidence on the potential public health impacts of emissions associated with shale gas extraction and has not currently identified any significant evidence that would make it change its views stated in its 2014 Review.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 09:45:26 answering member 4067 label Biography information for Steve Brine
tabling member	4073 label Biography information for Dr Sarah Wollaston

942538

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care what plans he has to ensure his Department continues to engage and meet with NHS England and Vertex to discuss access to Orkambi.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	164468
answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 10:09:26 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

942539

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether ensuring access to Orkambi for people with cystic fibrosis is a priority for his Department.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	164469
answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>It is a key commitment of this Government to ensure that people with comparatively rarer conditions, like cystic fibrosis, get the same quality, safety and efficacy in medicines as those who have more common conditions.</p><p> </p><p>However, it is also necessary that Vertex prices Orkambi fairly and responsibly. That is why we must go through the right process with Vertex and NHS England, not the Government, working together to secure the best outcome for patients. NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 10:10:54 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

942540

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether a date has been set for the next meeting between NHS England and Vertex to discuss access to the drug Orkambi.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	164470
answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>We are informed by NHS England that at the last meeting on 4 July, it was agreed that both parties would take time to reflect before a further meeting was arranged. NHS England has subsequently made a substantially increased proposal to Vertex and has offered to meet to discuss and clarify any aspects as required by the company.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 09:48:08 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

942541

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his Department's policy is on Vertex (a) waiving its confidentiality clause on the negotiations around NHS access to the drug Orkambi and (b) disclosing details of its offer to NHS England.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	164471
answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>It is not in the Department’s gift to impose any requirement upon Vertex to waive its confidentiality clause or to disclose details of any offer in the negotiations around National Health Service access to the drug Orkambi. However, Ministers at the department have publicly urged Vertex to consider the offer made by NHS England and to waive confidentiality so that we can all see, in the interests of transparency, the kind of prices it is seeking to charge the NHS.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 09:43:39 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

942568

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Obesity
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will support the research into whether obesity should be classified as a disease including the possible consequences of such a classification on NHS commissioning and other services.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	164437
answer	answer is ministerial correction date of answer 24/07/2018 answer text <p>There are no current plans for the Department to classify obesity as a disease.</p><p> </p><p>We will be launching the seven consultations announced in ‘Childhood obesity: a plan for action, chapter 2’ before the end of 2018. We will consider all responses to the consultations before setting out the next steps.</p><p> </p><p>‘Childhood obesity: a plan for action, chapter 2’ is available at the following link:</p><p> </p><p><a href="http://www.gov.uk/government/publications/childhood-obesity-a-plan-for-action-chapter-2" target="_blank">www.gov.uk/government/publications/childhood-obesity-a-plan-for-action-chapter-2</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 164438 question first answered 24/07/2018 15:09:11 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

942572

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Obesity: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his policy is on implementation of Chapter 2 of the Government's childhood obesity plan.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	164438
answer	answer is ministerial correction date of answer 24/07/2018 answer text <p>There are no current plans for the Department to classify obesity as a disease.</p><p> </p><p>We will be launching the seven consultations announced in ‘Childhood obesity: a plan for action, chapter 2’ before the end of 2018. We will consider all responses to the consultations before setting out the next steps.</p><p> </p><p>‘Childhood obesity: a plan for action, chapter 2’ is available at the following link:</p><p> </p><p><a href="http://www.gov.uk/government/publications/childhood-obesity-a-plan-for-action-chapter-2" target="_blank">www.gov.uk/government/publications/childhood-obesity-a-plan-for-action-chapter-2</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 164437 question first answered 24/07/2018 15:09:11 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon